Qualigen Therapeutics Gestione

Gestione criteri di controllo 0/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Kevin Richardson

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	less than a year
Proprietà del CEO	n/a
Durata media del management	less than a year
Durata media del Consiglio di amministrazione	2.6yrs

Aggiornamenti recenti sulla gestione

Recent updates

Qualigen Therapeutics GAAP EPS of -$0.11 beats by $0.06, revenue of $1.4M beats by $0.05M

Aug 16

Qualigen Therapeutics files mixed shelf offering of up to $150M

Jul 29

Qualigen partners Hande Sciences to support its application enabling studies for QN-302

Jul 06

Can Qualigen Therapeutics (NASDAQ:QLGN) Afford To Invest In Growth?

Mar 08

We're A Little Worried About Qualigen Therapeutics' (NASDAQ:QLGN) Cash Burn Rate

Nov 23

AMMINISTRATORE DELEGATO

Kevin Richardson (56 yo)

less than a year

Mandato

Mr. Kevin A. Richardson, II, is Interim CEO, Interim CFO & Director of Qualigen Therapeutics, Inc. from September 26, 2024 and serves as its Chairman since 2024. Mr. Richardson served as the Chairman at SA...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Michael Poirier	Chief Operating Officer	no data	US$632.70k	0.057% $ 1.3k
Kevin Richardson	Interim CEO	less than a year	Nessun dato	Nessun dato
Robert W. Becher	President & Director	less than a year	Nessun dato	Nessun dato
Christopher Lotz	VP of Finance & Corporate Secretary	2.2yrs	US$3.02m	0.0034% $ 75.9

0.5yrs

Durata media

57.5yo

Età media

Gestione esperta: Il team dirigenziale di QLGN non è considerato esperto (durata media 0.5 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Kevin Richardson	Interim CEO	less than a year	Nessun dato	Nessun dato
Robert W. Becher	President & Director	less than a year	Nessun dato	Nessun dato
Michael Gordon	Member of Scientific Advisory Board	2.6yrs	Nessun dato	Nessun dato
Anthony Tolcher	Member of Scientific Advisory Board	2.6yrs	Nessun dato	Nessun dato
Lillian Siu	Member of Scientific Advisory Board	2.6yrs	Nessun dato	Nessun dato
Robert Lim	Independent Director	less than a year	Nessun dato	Nessun dato
Wayne Klohs	Chair of Scientific Advisory Board	2.6yrs	Nessun dato	Nessun dato
Patricia M. LoRusso	Member of Scientific Advisory Board	2.6yrs	Nessun dato	Nessun dato
Christopher Slapak	Member of Scientific Advisory Board	2.6yrs	Nessun dato	Nessun dato
Braeden Lichti	Independent Director	less than a year	Nessun dato	Nessun dato
Stephen Neidle	Member of Scientific Advisory Board	2.6yrs	Nessun dato	Nessun dato
Cody Price	Independent Director	less than a year	Nessun dato	Nessun dato

2.6yrs

Durata media

49.5yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di QLGN non è considerato esperto (durata media del mandato 2.6 anni), il che suggerisce un nuovo consiglio.

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2025/03/12 17:01
Prezzo dell'azione a fine giornata	2025/03/12 00:00
Guadagni	2024/09/30
Guadagni annuali	2023/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Qualigen Therapeutics, Inc. è coperta da 2 analisti. 0 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
James Molloy	Alliance Global Partners
David Bautz	Zacks Small-Cap Research

Qualigen Therapeutics Gestione

Gestione criteri di controllo 0/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Qualigen Therapeutics, Inc. Announces Board and Committee Changes

Qualigen Therapeutics, Inc. Announces Chief Financial Officer Changes

Less than half of directors are independent

Qualigen Therapeutics, Inc., Annual General Meeting, Sep 17, 2024

Qualigen Therapeutics, Inc. Announces Board Changes

Qualigen Therapeutics, Inc. Announces Resignation of Amy Broidrick as President, Chief Strategy and Operating Officer and Director

Recent updates

Qualigen Therapeutics, Inc. announced that it has received $5.1 million in funding

Qualigen Therapeutics, Inc. announced that it expects to receive $4.5 million in funding

Qualigen Therapeutics to Implement a 1-for-50 Reverse Stock Split, to Regain Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market

Qualigen Therapeutics, Inc. has filed a Follow-on Equity Offering.

Qualigen Therapeutics Receives Non-Compliance Letter from Nasdaq Regarding Audit Committee

Qualigen Therapeutics, Inc. Announces Board and Committee Changes

Qualigen Therapeutics, Inc. Announces Chief Financial Officer Changes

New major risk - Financial data availability

Qualigen Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $3.458613 million.

Less than half of directors are independent

The Nasdaq Hearings Panel Grants Qualigen Therapeutics Until October 31, 2024 to Regain Compliance with the Bid Price Rule and the Equity Rule

Qualigen Therapeutics, Inc., Annual General Meeting, Sep 17, 2024

Qualigen Therapeutics, Inc. Announces Board Changes

Qualigen Therapeutics Receives Nasdaq Notice of a Delisting Determination Due to its Continued Non-Compliance with the Minimum Bid Price Requirement, Pursuant to Listing Rule 5550(b)(2)

Qualigen Therapeutics, Inc. announced delayed 10-Q filing

Qualigen Therapeutics, Inc. announced delayed annual 10-K filing

Qualigen Therapeutics, Inc. announced that it expects to receive $0.55 million in funding from Alpha Capital Anstalt

Consensus revenue estimates decrease by 14%, EPS upgraded

Qualigen Therapeutics Receives a Letter from the Nasdaq Stock Market

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Qualigen Therapeutics, Inc. Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors

Consensus EPS estimates fall by 57%

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Qualigen Therapeutics Announces UD FDA IND Clearance to Initiate Phase 1 Clinical Trial of Qn-302 for Treatment of Advanced or Metastatic Solid Tumors

Chembio Diagnostics, Inc. acquired FastPack® diagnostics business from Qualigen Therapeutics, Inc. (NasdaqCM:QLGN).

Chembio Diagnostics, Inc. acquired FastPack® diagnostics business from Qualigen Therapeutics, Inc. (NasdaqCM:QLGN).

New minor risk - Share price stability

Qualigen Therapeutics, Inc. Announces Resignation of Amy Broidrick as President, Chief Strategy and Operating Officer and Director

Poster Highlighting Qualigen Therapeutics’ Pan-RAS Inhibitor Platform Presented at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

Qualigen Therapeutics, Inc., Annual General Meeting, Jul 13, 2023

Qualigen Therapeutics, Inc. Announces the Resignation of Amy Broidrick as President, Chief Strategy and Operating Officer and A Director, Effective June 16, 2023

Price target decreased by 23% to US$27.00

Consensus revenue estimates decrease by 12%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Qualigen Therapeutics, Inc. Initiates Good Laboratory Practice Toxicology Studies on QN-302

Qualigen Therapeutics, Inc. Announces Executive Changes

Qualigen Therapeutics, Inc. announced that it expects to receive $3.3 million in funding

Qualigen Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule

Qualigen Therapeutics, Inc. Announces Pre-IND Feedback from U.S. Food and Drug Administration Regarding QN-302 for the Treatment of G4-Targeted Advanced Solid Tumors

Consensus forecasts updated

High number of new and inexperienced directors

Qualigen Therapeutics, Inc., Annual General Meeting, Oct 28, 2022

Nasdaq Grants Qualigen Therapeutics 180-Day Extension to February 27, 2023 to Regain Compliance with the Minimum Bid Price Requirement

High number of new and inexperienced directors

Consensus forecasts updated

Consensus revenue estimates increase by 10%

Qualigen Therapeutics, Inc. Announces Formation and First Meeting of QN-302 Scientific Advisory Board

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Qualigen Therapeutics GAAP EPS of -$0.11 beats by $0.06, revenue of $1.4M beats by $0.05M

Qualigen Therapeutics, Inc. Reports Positive Qn-247 Readout in Triple Negative Breast Cancer in Vivo Model

Qualigen Therapeutics files mixed shelf offering of up to $150M

Qualigen partners Hande Sciences to support its application enabling studies for QN-302

Price target decreased to US$5.75

Qualigen Therapeutics Announces IND-Enabling Studies to Advance Lead Program QN-302 Toward Clinical Trials

Qualigen Therapeutics, Inc. (NasdaqCM:QLGN) completed the acquisition of a 53% stake in NanoSynex Ltd. from shareholder.

Qualigen Therapeutics, Inc. (NasdaqCM:QLGN) entered into definitive agreement to acquire an unknown majority stake in NanoSynex Ltd. from shareholder.

Qualigen Therapeutics Appoints Shishir Sinha to Lead Diagnostics Division Following Promotion to Senior Vice President

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Can Qualigen Therapeutics (NASDAQ:QLGN) Afford To Invest In Growth?

We're A Little Worried About Qualigen Therapeutics' (NASDAQ:QLGN) Cash Burn Rate

Price target decreased to US$8.25

Second quarter 2021 earnings released: US$0.18 loss per share (vs US$2.12 loss in 2Q 2020)

First quarter 2021 earnings released: US$0.13 loss per share (vs US$0.16 loss in 1Q 2020)

AMMINISTRATORE DELEGATO

Mandato

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione